Skip to main content

Hemoglobin-Based Oxygen Carrier (HBOC) Development in Trauma: Previous Regulatory Challenges, Lessons Learned, and a Path Forward

  • Chapter
  • First Online:
Blood Substitutes and Oxygen Biotherapeutics
  • 559 Accesses

Abstract

Historically, hemoglobin-based oxygen carriers (HBOCs) were being developed as “blood substitutes,” despite their transient circulatory half-life (~ 24 h) vs. transfused red blood cells (RBCs). More recently, HBOC commercial development focused on “oxygen therapeutic” indications to provide a temporary oxygenation bridge until medical or surgical interventions (including RBC transfusion, if required) can be initiated. This included the early trauma trials with HemAssist® (Baxter), Hemopure® (Biopure) and PolyHeme® (Northfield) for resuscitating hypotensive shock. These trials all failed due to safety concerns (e.g., cardiac events, mortality) and certain protocol design limitations. In 2008 the Food and Drug Administration (FDA) put all HBOC trials in the US on clinical hold due to the unfavorable benefit: risk profile demonstrated by various HBOCs in different clinical studies in a meta-analysis published by Natanson et al. (2008). During standard resuscitation in trauma, organ dysfunction and failure can occur due to ischemia in critical tissues, which can be detected by the degree of lactic acidosis. Sangart’s Phase 2 trauma program with MP4OX therefore added lactate >5 mmol/L as an inclusion criterion to enroll patients who had lost sufficient blood to cause a tissue oxygen debt. This was key to the successful conduct of their Phase 2 program (ex-US, from 2009 to 2012) to evaluate MP4OX as an adjunct to standard fluid resuscitation and transfusion of RBCs. In 2013, Sangart shared their Phase 2b results with the FDA, and succeeded in getting the FDA to agree that a planned Phase 2c higher dose comparison study of MP4OX in trauma could include clinical sites in the US. Unfortunately, Sangart failed to secure new funding and was forced to terminate development and operations in Dec 2013, even though a regulatory path forward with FDA approval to proceed in trauma had been achieved.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Epstein JS, Jaffe HW, Alter HJ, et al. Blood system changes since recognition of transfusion-associated AIDS. Transfusion. 2013;53:2365–74.

    Article  Google Scholar 

  2. Mitchell P, Weiskopf R, Zapol WM. NIH/FDA/DOD interagency working group on oxygen therapeutics. In: Kim HW, Greenburg AG, editors. Hemoglobin-based oxygen carriers as red cell substitutes and oxygen therapeutics. Berlin: Springer; 2013. p. 141–7.

    Chapter  Google Scholar 

  3. Kauvar DS, Wade CE. The epidemiology and modern management of traumatic hemorrhage: US and international perspective. Crit Care. 2005;9:S1–9.

    Article  Google Scholar 

  4. Abramson D, Scalea TM, Hitchcock R, et al. Lactate clearance and survival following injury. J Trauma. 1993;35:584–9.

    Article  CAS  Google Scholar 

  5. Manikis P, Jankowski S, Zhang H, et al. Correlation of serial blood lactate levels to organ failure and mortality after trauma. Am J Emerg Med. 1995;13:619–22.

    Article  CAS  Google Scholar 

  6. Regnier MA, Raux M, Le Manach Y, et al. Prognostic significance of blood lactate and lactate clearance in trauma patients. Anesthesiology. 2012;117:1276–88.

    Article  CAS  Google Scholar 

  7. Lefering R, Zielske D, Bouillon B, et al. Lactic acidosis is associated with multiple organ failure and need for ventilator support in patients with severe hemorrhage from trauma. Eur J Trauma Emerg Surg. 2013;39(5):487–93. https://doi.org/10.1007/s00068-013-0285-3.

    Article  CAS  PubMed  Google Scholar 

  8. Jahr JS, Akha AS, Holtby RJ. Crosslinked, polymerized, and PEG-conjugated hemoglobin-based oxygen carriers: clinical safety and efficacy of recent and current products. Curr Drug Discov Technol. 2012;9:158–65.

    Article  CAS  Google Scholar 

  9. Brohi K, Plani F, Moeng M, et al. Multicenter randomized controlled trial TRA-204 to evaluate the safety and efficacy of MP4OX in lactate clearance following trauma hemorrhage. Crit Care Med. 2010;38:749.

    Google Scholar 

  10. Brohi K, Levy H, Keipert PE, et al. Normalization of lactate within 8 hours or ≥20% clearance in initial 2 hours correlate with outcomes from traumatic hemorrhage. Crit Care Med. 2011;39:643.

    Article  Google Scholar 

  11. Brohi K, Boffard K, Zielske D, et al. Effects of MP4OX, an oxygen therapeutic, on clinical outcomes in trauma patients with hemorrhagic shock: a phase IIb multi-center randomized placebo-controlled trial. Poster presentation: American Association for the Surgery of Trauma (AAST) meeting, San Francisco. 2013.

    Google Scholar 

  12. US Food and Drug Administration. Draft guidance for industry: criteria for safety and efficacy evaluation of oxygen therapeutics as red blood cell substitutes. Issued Oct 2004 www.rsihata.com/updateguidance/usfda2/bio1/ucm080290. 2004.

  13. Silverman TA, Weiskopf RB. Hemoglobin-based oxygen carriers: current status and future directions. Anesthesiology. 2009;111:946–63.

    Article  Google Scholar 

  14. Natanson C, Kerns SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death. A meta-analysis. JAMA. 2008;299:2304–12.

    Article  CAS  Google Scholar 

  15. Letters to the Editor (2008) Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 300:1295–1300.

    Google Scholar 

  16. Olofsson CI, Górecki AZ, Dirksen R, et al. Evaluation of MP4OX for prevention of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia: a randomized, double-blind, multicenter study. Anesthesiology. 2011;114:1048–63.

    Article  CAS  Google Scholar 

  17. Van der Linden P, Gazdzik TS, Jahoda D, et al. A double-blind, randomized, multicenter study of MP4OX for treatment of perioperative hypotension in patients undergoing primary hip arthroplasty under spinal anesthesia. Anesth Analg. 2011;112:759–73.

    Article  Google Scholar 

  18. Winslow RM. Clinical indications for blood substitutes and optimal properties. In: Winslow RM, editor. Blood substitutes. London: Elsevier; 2006. p. 115–25.

    Chapter  Google Scholar 

  19. Misra H, Lickliter J, Kazo F, et al. Pegylated carboxyhemoglobin bovine (Sanguinate): results of a phase I clinical trial. Artif Organs. 2014;38:702–7.

    Article  CAS  Google Scholar 

  20. Hsia JC, Ma L. Compositions and methods of use of neurovascular protective multi- functional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine. 2012. US Patent 8273857B2 (https://patents.google.com/patent/US8273857B2/en).

  21. Hsia CJC, Ma L. A hemoglobin-based multifunctional therapeutic: polynitroxylated pegylated hemoglobin. Artif Organs. 2012;36:215–20.

    Article  Google Scholar 

  22. Zhang J, Cao S, Ma L, et al. Protection from transient focal cerebral ischemia by transfusion of polynitroxylated pegylated hemoglobin. Stroke. 2013;44:A154.

    Google Scholar 

  23. Shellington DK, Du L, Wu X, et al. Polynitroxylated pegylated hemoglobin: a novel neuroprotective hemoglobin for acute volume-limited fluid resuscitation after combined traumatic brain injury and hemorrhagic hypotension in mice. Crit Care Med. 2011;39:494–505.

    Article  CAS  Google Scholar 

  24. Brockman EC, Bayir H, Blasiole B, et al. Polynitroxylated-pegylated hemoglobin attenuates fluid requirements and brain edema in combined traumatic brain injury plus hemorrhagic shock in mice. J Cereb Blood Flow Metab. 2012;33:1457–64.

    Article  Google Scholar 

Download references

Acknowledgments

PEK was formerly employed by Sangart Inc. (San Diego, CA) as VP, Clinical Development, during the conduct of the MP4OX clinical trials in trauma.

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Keipert, P.E. (2022). Hemoglobin-Based Oxygen Carrier (HBOC) Development in Trauma: Previous Regulatory Challenges, Lessons Learned, and a Path Forward. In: Liu, H., Kaye, A.D., Jahr, J.S. (eds) Blood Substitutes and Oxygen Biotherapeutics. Springer, Cham. https://doi.org/10.1007/978-3-030-95975-3_41

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-95975-3_41

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-95974-6

  • Online ISBN: 978-3-030-95975-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics